Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 67 • 2017 Pediatric Rheumatology Symposium
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
Courtney McCracken¹, Curtis Travers¹, Kirsten Jenkins², Carolyn Drews-Botsch³, Steven Yeh⁴, Sampath Prahalad^1,5 and Sheila Angeles-Han^6,7, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, University of Cincinnati, Cincinnati, OH
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor-α inhibitors (TNFi) are common treatments for children with chronic non-infectious uveitis (NIU). Optimal duration of treatment prior to…
Abstract Number: 11 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry
Hermine Brunner¹, Nicolino Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹³, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason A Dare¹⁶, Mareike Bereswill¹⁷, Jasmina Kalabic¹⁷, Hartmut Kupper¹⁸, Daniel J. Lovell¹⁹ and Alberto Martini², ¹Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³Seattle Childrens Hospital, Bayside, NY, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁶Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁷Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Orthopädiezentrum Altona, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Clinical Oncology/Immunology, AbbVie Deutschland GmbH & Co. KG, Ludnigshafen, Germany, ¹⁹Rheumatology MLC 4010, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 48 • 2017 Pediatric Rheumatology Symposium
Methotrexate use and route of administration in JIA: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Fenglong Xie², Yukiko Kimura³, Laura E. Schanberg⁴, Timothy Beukelman⁵ and and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Navita L. Mallalieu¹, Joy Hsu¹, Karen Wang¹, Sunethra Wimalasundera², Chris Wells², Inmaculada Calvo Penades³, Rubén J. Cuttica⁴, Hans-Iko Huppertz⁵, Rik Joos⁶, Yukiko Kimura⁷, Diana Milojevic⁸, Margalit Rosenkranz⁹, Kenneth Schikler¹⁰, Tamas Constantin¹¹ and Carine Wouters¹², ¹Roche Innovation Center, New York, NY, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Hospital Universitario y Polytécnico La Fe, Valencia, Spain, ⁴Hospital General de Niños Pedro de Elizalde, Buenes Aires, Argentina, ⁵Professor Hess Children's Hospital, Bremen, Germany, ⁶ZNA Jan Palfijn Antwerpen, Antwerp, Belgium, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Tufts Medical Center, Boston, MA, ⁹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ¹⁰University of Louisville Hospital, Louisville, KY, ¹¹Semmelweis University, Budapest, Hungary, ¹²University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…
Abstract Number: 141 • 2017 Pediatric Rheumatology Symposium
Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹, Yang Liu², Pan Zheng² and Lawrence Jung³, ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Cancer and Immunology Research Center, Children's National Medical Center, Washington, DC, ³Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: Monocytes plays a role in juvenile idiopathic arthritis (JIA). CD14dim monocytes have modulatory effects in innate and adaptive immune responses. Siglec-10, which is highly…
Abstract Number: 41 • 2017 Pediatric Rheumatology Symposium
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet Ramanan³, Rubén Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson⁶, Heinrike Schmeling⁷, Jordi Anton⁸, Kirsten Minden⁹, Joy Hsu¹⁰, Kamal Bharucha¹¹, Sunethra Wimalasundera¹², Alysha K. Kadva¹³, Ruchi Upmanyu¹², Navita L. Mallalieu¹⁰, Daniel Lovell⁶ and Fabrizio De Benedetti¹⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁷University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁸Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Charité – University of Medicine Berlin, Berlin, Germany, ¹⁰Roche Innovation Center, New York, NY, ¹¹Genentech, South San Francisco, CA, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹³Genentech, San Francisco, CA, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: The efficacy and safety of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor-alpha inhibitor, have been demonstrated in patients (pts) with polyarticular-course juvenile idiopathic…
Abstract Number: 12 • 2017 Pediatric Rheumatology Symposium
Use of Ultrasound to Determine Remission Status in Children with Juvenile Idiopathic Arthritis
Ottar Kristinsson¹, Lisabeth Scalzi², Michael Bruno², Cristy French², Vernon Chinchilli² and Brandt Groh², ¹Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ²Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: The ultimate goal for clinicians caring for children with Juvenile idiopathic arthritis (JIA) is to attain disease remission off medications. Correct identification of remission…
Abstract Number: 135 • 2017 Pediatric Rheumatology Symposium
Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage
Janneke Peeters¹, Arjan Boltjes^2,3, Stephin Vervoort⁴, Paul Coffer¹, Bas Vastert^2,5, Femke van Wijk^2,3, Michal Mokry³, Teun de Vries^6,7 and Jorg van Loosdregt³, ¹Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Peter MacCallum Cancer Centre, Melbourne, Australia, ⁵Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral Cell Biology and Functional Anatomy, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands, ⁷Department of Periodontology, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a multifactorial autoimmune disease characterized by the accumulation of various immune cells, including monocytes, in the joint synovial fluid…
Abstract Number: 64 • 2017 Pediatric Rheumatology Symposium
Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Tommy Gerschman¹, Jordan Raugust², Julia Brooks³, Nicole Johnson¹, Nadia Luca⁴, Rebeka Stevenson¹, Heinrike Schmeling⁵, Paivi Miettunen¹ and Susanne Benseler⁴, ¹Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, ³Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁵University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Children with JIA are increasingly being encouraged to be physically active and are participating in organized and competitive sports as youth athletes. These youth…
Abstract Number: 22 • 2017 Pediatric Rheumatology Symposium
Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis
Gabriela Guefen¹, Kirsten Jenkins², Lori Ponder², Kelly A. Rouster-Stevens^2,3, Patricia Vega-Fernandez^2,3, Elaine S Ramsay^2,3, Sheila Angeles-Han^2,3 and Sampath Prahalad^2,3,4, ¹College of Arts and Sciences, Emory University, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Human Genetics, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Treatments include disease modifying anti-rheumatic drugs, commonly methotrexate (MTX), biologics including Etanercept…
Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Treatment Outcomes in Down’s Arthropathy
Jordan T. Jones¹ and Leena Danawala², ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium
Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies
Kelly Wise¹, Dustin Lewis², Bethanne Thomas², Karla Jones³, Stephanie Lemle², Darby MacDonald², Fatima Barbar-Smiley², Vidya Sivaraman² and Cagri Yildirim-Toruner³, ¹Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes. Biologics,…
Abstract Number: 52 • 2017 Pediatric Rheumatology Symposium
How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study
Daniel B. Horton^1,2, Jomaira Salas³, Aleksandra Wec⁴, Timothy Beukelman^5,6, Alexis Boneparth¹, Ky Haverkamp⁷, Melanie Kohlheim⁸, Melissa Mannion⁵, Nandini Moorthy¹, Sarah Ringold⁹ and Marsha Rosenthal², ¹Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ³Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁴Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Family Medicine, University of Washington School of Medicine, Seattle, WA, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Seattle Children's Hospital, Seattle, WA
Background/Purpose: Prior research has examined factors important to clinicians in deciding whether to withdraw therapy for inactive JIA, but little is known about the perspectives…
Abstract Number: 148 • 2017 Pediatric Rheumatology Symposium
Oral Microbial Profile in Juvenile Idiopathic Arthritis
Sriharsha Grevich^1,2, Peggy Lee³, Jeffrey McLean³, Brian Leroux³, Sarah Ringold^1,2, Kyle Hager⁴, Mitchell Brittnacher⁴, Hillary Hayden⁴, Samuel Miller⁴ and Anne Stevens^1,2,5, ¹University of Washington, Department of Pediatrics, Seattle, WA, ²Seattle Children's Hospital, Seattle, WA, ³University of Washington, School of Dentistry, Seattle, WA, ⁴University of Washington, Department of Microbiology, Seattle, WA, ⁵Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Microbial communities in the mouth have been associated with the chronic inflammation of periodontitis and rheumatoid arthritis (RA), and there is higher prevalence of…
Abstract Number: 139 • 2017 Pediatric Rheumatology Symposium
Dysregulation of miRNA in mononuclear cells of patients with enthesitis related arthritis
Amita Aggarwal¹ and Sushma Singh², ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Enthesitis related arthritis (ERA) is the most common category of JIA in Asia. Identifying dysregulated microRNA may help in understanding the pathogenesis of ERA.…

« Previous Page
1
…
8
9
10
11
12
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].